Fosun Pharma's Subsidiary Receives Approval for FXR0906 Injection Clinical Trial

Stock News07-15

An announcement from Shanghai Fosun Pharmaceutical (Group) Co.,Ltd. (600196.SH) reveals that its controlling subsidiary, Fosun Pharma Industrial Development (Shenzhen) Co., Ltd., has received approval from the National Medical Products Administration.

The approval is for the initiation of a clinical trial for the FXR0906 injection, intended for the treatment of hypertriglyceridemia.

Following the necessary preparations, the subsidiary plans to commence a Phase I clinical study for this drug within mainland China.

The FXR0906 injection is an siRNA therapeutic, developed through RNA interference technology to target the liver and silence the APOC3 gene.

This mechanism is designed to lower serum triglyceride levels, offering a potential treatment for hypertriglyceridemia.

The company and its subsidiaries hold exclusive rights for the research, development, registration, production, and commercialization of this product in mainland China, Hong Kong, and Macau.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1123458410?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-15 17:50","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1123458410","market":"sh","top_or_hot":-1,"title":"Fosun Pharma's Subsidiary Receives Approval for FXR0906 Injection Clinical Trial","media":"Stock News","content":"<p>An announcement from <b>Shanghai Fosun Pharmaceutical (Group) Co.,Ltd.</b> (<b>600196.SH</b>) reveals that its controlling subsidiary, Fosun Pharma Industrial Development (Shenzhen) Co., Ltd., has received approval from the National Medical Products Administration.<br><br>The approval is for the initiation of a clinical trial for the FXR0906 injection, intended for the treatment of hypertriglyceridemia.<br><br>Following the necessary preparations, the subsidiary plans to commence a Phase I clinical study for this drug within mainland China.<br><br>The FXR0906 injection is an siRNA therapeutic, developed through RNA interference technology to target the liver and silence the APOC3 gene.<br><br>This mechanism is designed to lower serum triglyceride levels, offering a potential treatment for hypertriglyceridemia.<br><br>The company and its subsidiaries hold exclusive rights for the research, development, registration, production, and commercialization of this product in mainland China, Hong Kong, and Macau.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Fosun Pharma's Subsidiary Receives Approval for FXR0906 Injection Clinical Trial</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFosun Pharma's Subsidiary Receives Approval for FXR0906 Injection Clinical Trial\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-07-15 17:50</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>An announcement from <b>Shanghai Fosun Pharmaceutical (Group) Co.,Ltd.</b> (<b>600196.SH</b>) reveals that its controlling subsidiary, Fosun Pharma Industrial Development (Shenzhen) Co., Ltd., has received approval from the National Medical Products Administration.<br><br>The approval is for the initiation of a clinical trial for the FXR0906 injection, intended for the treatment of hypertriglyceridemia.<br><br>Following the necessary preparations, the subsidiary plans to commence a Phase I clinical study for this drug within mainland China.<br><br>The FXR0906 injection is an siRNA therapeutic, developed through RNA interference technology to target the liver and silence the APOC3 gene.<br><br>This mechanism is designed to lower serum triglyceride levels, offering a potential treatment for hypertriglyceridemia.<br><br>The company and its subsidiaries hold exclusive rights for the research, development, registration, production, and commercialization of this product in mainland China, Hong Kong, and Macau.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0060","symbol_name":"抗癌","start_time":0,"source_url":"","article_id":"1123458410","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1123458410","pubTimestamp":1784109024,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"An announcement from Shanghai Fosun Pharmaceutical (Group) Co.,Ltd. (600196.SH) reveals that its controlling subsidiary, Fosun Pharma Industrial Development (Shenzhen) Co., Ltd., has received...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"600196":"复星医药","BK0060":"抗癌","BK0187":"一线龙头","02196":"复星医药","BK0175":"白马股","BMED":"iShares Health Innovation Active ETF","BK0028":"国家队","BK0239":"医药制造","BK0196":"行业龙头","BK0183":"MSCI概念","BK0096":"民营医院","BK1515":"抗疫概念","BK1191":"制药","BK0188":"融资融券","BK0012":"证金概念","BK1593":"医美概念股","IBBQ":"Invesco Nasdaq Biotechnology ETF"},"translate_title":"复星医药子公司获FXR0906注射液临床试验批件","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"600196":1,"BMED":1,"IBBQ":1,"02196":1},"content_text":"An announcement from Shanghai Fosun Pharmaceutical (Group) Co.,Ltd. (600196.SH) reveals that its controlling subsidiary, Fosun Pharma Industrial Development (Shenzhen) Co., Ltd., has received approval from the National Medical Products Administration.The approval is for the initiation of a clinical trial for the FXR0906 injection, intended for the treatment of hypertriglyceridemia.Following the necessary preparations, the subsidiary plans to commence a Phase I clinical study for this drug within mainland China.The FXR0906 injection is an siRNA therapeutic, developed through RNA interference technology to target the liver and silence the APOC3 gene.This mechanism is designed to lower serum triglyceride levels, offering a potential treatment for hypertriglyceridemia.The company and its subsidiaries hold exclusive rights for the research, development, registration, production, and commercialization of this product in mainland China, Hong Kong, and Macau.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.46.0","shortVersion":"4.46.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1123458410","isCrawlerRequest":true}